Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Cerity Partners LLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,056 shares of the company’s stock after selling 1,185 shares during the period. Cerity Partners LLC’s holdings in Protagonist Therapeutics were worth $518,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Maryland State Retirement & Pension System grew its stake in shares of Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock worth $779,000 after buying an additional 278 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after purchasing an additional 295 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV grew its position in Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock valued at $81,000 after purchasing an additional 737 shares during the last quarter. Finally, WINTON GROUP Ltd increased its stake in Protagonist Therapeutics by 3.0% during the 4th quarter. WINTON GROUP Ltd now owns 26,768 shares of the company’s stock valued at $1,033,000 after purchasing an additional 785 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analysts Set New Price Targets

PTGX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Wedbush reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, March 28th. BMO Capital Markets boosted their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Finally, BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $65.44.

Protagonist Therapeutics Stock Down 1.0 %

NASDAQ PTGX opened at $45.80 on Tuesday. The company has a 50-day moving average price of $45.03 and a 200-day moving average price of $42.80. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The firm has a market capitalization of $2.81 billion, a P/E ratio of 17.22 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The business had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Buying and Selling

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total transaction of $204,606.62. Following the sale, the chief executive officer now directly owns 540,260 shares in the company, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Asif Ali sold 24,903 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the transaction, the chief financial officer now directly owns 62,821 shares of the company’s stock, valued at approximately $3,689,477.33. This trade represents a 28.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 64,776 shares of company stock valued at $3,585,010. 5.40% of the stock is owned by company insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.